Oruka Therapeutics/$ORKA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Oruka Therapeutics
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.
- Ticker
- $ORKA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- Menlo Park, United States
- Website
- orukatx.com
ORKA Metrics
BasicAdvanced
$6.8B
-
-$2.02
-0.21
-
Price and volume
Market cap
$6.8B
Beta
-0.21
52-week high
$115.52
52-week low
$25.23
Average daily volume
925K
Financial strength
Current ratio
38.513
Quick ratio
38.034
Long term debt to equity
0.002
Total debt to equity
0.002
Profitability
EBITDA (TTM)
-154.943
Management effectiveness
Return on assets (TTM)
-12.95%
Return on equity (TTM)
-18.23%
Valuation
Price to book
5.65
Price to tangible book (TTM)
5.65
Price to free cash flow (TTM)
-55.103
Free cash flow yield (TTM)
-1.81%
Free cash flow per share (TTM)
-1.867
Growth
Earnings per share change (TTM)
-5.54%
What the Analysts think about ORKA
Analyst ratings (Buy, Hold, Sell) for Oruka Therapeutics stock.
Analyst projections of the future price of Oruka Therapeutics stock.
Bulls say / Bears say
ORKA-001’s Phase 2b trial reproduced strong results: 61% of patients on the high dose achieved complete skin clearance at Week 16, versus none on placebo, with a safety profile the company described as favourable. This strengthens confidence that the earlier efficacy signal was not a one-off. (GlobeNewswire)
The initial ORKA-001 study showed skin clearance continuing to improve after the last dose: at Week 28, 71.4% of treated patients had complete clearance and 87.3% had near-complete clearance. If longer follow-up confirms this durability, infrequent dosing could be a useful selling point. (Practical Dermatology)
Oruka reported $1.1 billion in cash and marketable securities at the end of June 2026, which it expects to fund development through an ORKA-001 application for approval and continued work on ORKA-002. That gives the company substantial room to advance its pipeline without an immediate need to raise more capital. (U.S. Securities and Exchange Commission)
ORKA-001’s apparent efficacy edge over existing psoriasis drugs is uncertain: the Phase 2a trial did not compare it directly with those treatments, and only 63 patients received the drug. Cross-trial comparisons cannot show that it is superior. (BioPharma Dive)
ORKA-002 is less advanced: its psoriasis Phase 2 results were scheduled for 1Q 2027, and its Phase 2 hidradenitis suppurativa study had only recently started. Its efficacy in patients and the hoped-for less frequent dosing therefore remain unproven. (U.S. Securities and Exchange Commission)
Oruka has no approved products or sales and expects substantial losses as development spending rises. Investors therefore depend on future clinical and regulatory success before the company can generate product revenue. (U.S. Securities and Exchange Commission)
Data summarised monthly by Lightyear AI. Last updated on 26 Oct 2026.
ORKA Financial Performance
Revenues and expenses
ORKA Earnings Performance
Company profitability
Upcoming events
No upcoming events
ORKA News
AllArticlesVideos
Funds containing ORKA
Fund name | Fund size | $ORKA weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.42% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.42% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.17% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.17% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $3.2B | 0.05% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.